DRUG logo

DRUGBright Minds Biosciences Inc

$60.48
$0.47
(0.77%)
Today
Updated: 10:26 AM EDT
Reported EarningsMay 19
Mkt Cap$596.53M
Vol226,496.00
News
all
press releases
Why a $5 Million New Position Signals Confidence in This Epilepsy Drug Pipeline
Key PointsB Group bought 67,500 shares of Bright Minds Biosciences in the first quarter...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Insider Selling: Bright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Sells 109,331 Shares of Stock
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) major shareholder Cormorant Asset Management, Lp sold 109,331 shares of the company's stock in a transaction dated Tuesday, April 28th...
MarketBeat
News Placeholder
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are currently covering the stock...
MarketBeat
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen
Wall Street Zen cut shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday...
MarketBeat
News Placeholder
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Growth in Short Interest
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) was the target of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 703,646...
MarketBeat
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group
Jefferies Financial Group began coverage on shares of Bright Minds Biosciences in a research note on Monday. They set a "buy" rating and a $145.00 price objective for the company...
MarketBeat
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Here's Why
Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap Up - Should You Buy...
MarketBeat
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.4% Higher - What's Next?
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 7.4% - Here's Why...
MarketBeat
News Placeholder
Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from BTIG Research
BTIG Research reissued a "buy" rating and issued a $147.00 target price on shares of Bright Minds Biosciences in a research note on Monday...
MarketBeat
News Placeholder
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Average Recommendation of "Moderate Buy" from Brokerages
Bright Minds Biosciences Inc. (NASDAQ:DRUG - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the firm, MarketBeat.com reports. One...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.